High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients

Maria Bach Laursen(Chr. Hansen (Denmark)), Karen Dybkær(Aalborg University Hospital), Anna A. Schönherz(Aalborg University Hospital), Linn Reinholdt(Aalborg University Hospital), Alexander Schmitz(Chr. Hansen (Denmark)), Hans Erik Johnsen(Herlev Hospital), Julie Støve Bødker(Chr. Hansen (Denmark)), Steffen Falgreen(Chr. Hansen (Denmark)), Suzette Sørensen(North Denmark Region), Hanne Due(Aalborg University Hospital), Martin Bøgsted(Chr. Hansen (Denmark)), Rasmus Røge(Aalborg University Hospital), Ditte Starberg Jespersen(Aalborg University Hospital), Marianne Schmidt Ettrup(Aalborg University Hospital), Lykke Grubach(Aalborg University Hospital)

Oncotarget

January 22, 2019

10.18632/oncotarget.26588

Cited by 28

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma

|Blood|2009|390

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Leukemia|2012|362

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

|Leukemia|2015|256